Specimen Orientation by Marking the Peripheral End: (Potential) Clinical Advantages in Prostate Biopsy by Galosi, Andrea Benedetto et al.
Hindawi Publishing Corporation
Prostate Cancer
Volume 2011, Article ID 270403, 7 pages
doi:10.1155/2011/270403
Review Article
SpecimenOrientation by Marking the PeripheralEnd:
(Potential) Clinical Advantages in Prostate Biopsy
Andrea Benedetto Galosi,1 GiovanniMuzzonigro,1
Vito Lacetera,1 andRoberta Mazzucchelli2
1Institute of Urology, Azienda Ospedaliero Universitaria, United Hospitals, Torrette, 60126 Ancona, Italy
2Section of Pathological Anatomy, School of Medicine, Marche Polytechnic University and Azienda Ospedaliero Universitaria,
United Hospitals, 60126 Ancona, Italy
Correspondence should be addressed to Andrea Benedetto Galosi, galosiab@yahoo.it
Received 19 May 2011; Accepted 25 May 2011
Academic Editor: R. Montironi
Copyright © 2011 Andrea Benedetto Galosi et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
The aim of this paper is to identify advantages that could be obtained by orientation of the biopsy specimen using the marking
technique. We reviewed our experience (4,500 cases) and the published literature. The peripheral (proximal) end of the fresh
specimen is marked with ink soon after needle delivering in a few minutes. It is performed easily in association with pre-
embedding method. Five potential clinical advantages were identiﬁed: (1) tumor localization, (2) atypical lesions localization
and planning rebiopsy strategy, (3) planning surgical strategy, (4) selection criteria for focal therapy and active surveillance, and
(5) cost reduction. Peripheral end marking is low cost, easy and reproducible. It drives several potential advantages in cancer
diagnosisorisolatedatypicallesions,inparticular,spatiallocalizationwithinthebiopsy(transitionversusperipheralzone,anterior
versus posterior, subcapsular versus intraparenchima, and extraprostatic extension) should be easy and reliable. We can add a new
pathological parameter: pathological orientation or biopsy polarity.
1.Introduction
PSA-driven diagnosis of Pca leads to overdiagnosis and over-
treatment in part of the patient population [1]. With the
advancement of active surveillance and image-guided focal
therapies(brachytherapy,cryotherapy,andhigh-intensityfo-
cused ultrasound) as well as nerve-sparing radical surgery,
the anatomical location of cancer at biopsy has become im-
portant and assumes a prominent role in treatment planning
[2].
S e v e r a la t t e m p t s[ 3, 4] have been made to improve the
preoperative topographic distribution of prostate cancer in
terms of number of positive cores, laterality, area of sampling
(apex, mid, base), or anterior versus posterior gland. Even
3-dimensional prostate mapping based on transperineal sat-
uration biopsy has been proposed to guide (focal or total)
treatment strategy [5, 6].
Specimen orientation by marking the peripheral (prox-
imal) end of the biopsy specimen may have several clinical
advantages in order to improve the anatomical location of
the cancer. Since transrectal ultrasound biopsy is the world-
wide used technique for Pca diagnosis, marking the periph-
eralendofthecorebiopsycouldeasilyidentifythesubcapsu-
lar tissue of the peripheral zone just close to the ultrasound
probe. Only very few published papers describe the pros and
cons of the marking technique [7–10].
Hypothetically, one could have four clinical scenarios if
the marking of the peripheral (proximal) end of the biopsy
is performed and reported by pathologist: (1) Pca reach the
marked end, meaning that subcapsular peripheral zone is
involved if transrectal biopsy has been used; (2) Pca is not
in contact with the marked end, thus normal tissue is present
in the subcapsular area, and the distance could be measured
in each specimen; (3) both ends of the specimen are free of
cancer, which could be interpreted as intragland cancer or
tangential sampling of larger cancer located laterally to
biopsytrack;(4)Pcaliesinthenoninkedendofthespecimen
(distal or anterior), which can be interpreted as anterior
cancer.2 Prostate Cancer
Figure 1: Fresh specimens of PB pre-embedded in tissue cassettes.
The peripheral end of each biopsy was marked using black ink.
This hypothetical information could also be applied to
isolated atypical lesions (or atipical small acinar prolifera-
tion, ASAP) detected on initial biopsy. Using marking tech-
niques, we add more details on the anatomical location of
ASAP that could be useful in the sampling strategy in case of
repeat biopsy.
The aim of this study is to identify all advantages that
could be obtained by orientation of the biopsy specimen us-
ing the marking technique. We reviewed our experience and
the published literature.
2. Methods
A MEDLINE search using keywords and MeSH term
(“Prostatic Neoplasms/pathology” (Mesh) AND “Biopsy”
(Mesh) AND “Staining and Labeling” (Mesh) OR “quality”
OR “marking” OR “inking” (all ﬁelds)) was performed for
entries between 01-01-1966 to 03-03-2011. 93 articles were
retrieved from the search. In order to evaluateall papers ded-
icated to tissue marking techniques on prostate biopsy (PB)
specimens, we selected the 35 most relevant articles based
on title and abstract. Furthermore we reviewed our prostate
biopsy database composed by 4,500 cases, most of them
using the pre-embedding technique plus inking the periph-
eral end of PB. We described our technique in previous
reports [11, 12]. Therefore, results are based on literature
search and our experience.
2.1. Technique of Marking Biopsy Specimen. The marking
technique can be applied to pre-embedded specimens by
urologists, radiologists, or nurses in few minutes just before
formalin ﬁxation (Figure 1). The marking technique cannot
be applied to free-ﬂoating specimens in formalin vials [13].
The proximal end of the fresh biopsy specimen is marked
with ink (usually black ink) on the bench soon after needle
delivering. Then the specimen is placed on nylon mesh (or
sponges) and then covered with another nylon mesh accord-
ing to the pre-embedding methods of prostate needle biopsy
specimens described by Rogatsch et al. [13]. The specimen is
closed and stretched between 2 nylon meshes and placed in
a tissue-labelled cassette. One or two biopsy specimens are
collected in the same cassette identiﬁed by site and prostate
Figure 2: The inked end was always recognized at pathological
analysis using microscope.
lobe. Afterwards the tissue cassettes were submitted in con-
tainers ﬁlled with 10% buﬀered formalin to obtain complete
specimen ﬁxation and dehydration. After ﬁxation, all tissue
cores were embedded in paraﬃn blocks and then sectioned.
The inked end was always easily recognized at the patho-
logical analysis, also in our experience (Figure 2). We called
the original pre-embedding technique “sandwich technique”
with the addition of few modiﬁcations [11, 12].
(1) Nylon meshes (sponges) must be squeezed in saline
solution to have fully soaked sponges (without air
bubbles). This is very important preliminary step to
biopsy specimen release, since it allows subsequent
formalin diﬀusion and specimen ﬁxation. If air bub-
bles were within the mesh, they could prevent for-
malin diﬀusion. Therefore only soaked sponge with
saline solution allows complete specimen ﬁxation
and dehydration, without loss of ink. Furthermore,
any potential dangerous exposure (patient or nurses)
with formalin solution (contact or exhalation) is
avoided using saline solution.
(2) Biopsy specimens are delivered from the needle
directly on nylon mesh, in order to avoid any manip-
ulation, or changes in orientation, or loss of frag-
mented cores.
(3) The procedure is sterile because meshes and cassettes
can be treated in sterilization centre or prepacked.
Other authors [14] described that cassettes were soaked
in a glass full of Bouin solution for 1 second before formalin
toallowaninkﬁxationonthetissue.Ourexperiencerevealed
that this technique was not needed and more time consum-
ing.
Many leading genitourinary pathologists and guidelines
[15, 16] recommend the pre-embedding technique, which
is considered the best one for processing and submission of
PB specimens. The multipack container kits [17]a r et e c h -
nically more complex and costly [18]; however, in 2 clinical
randomized studies [19, 20] and one experimental study
[21], a decreased rate of equivocal diagnosis (atypical glands
and ASAP).Prostate Cancer 3
3. Results
Markingtechniqueis performedeasilyonthe freshspecimen
in association with pre-embedding method of prostate biop-
sy. The inked PB end was always recognized at pathological
analysis by pathologists using microscope. Five potential
clinical advantages were identiﬁed using prostate biopsy
specimen orientation by marking the peripheral end. We re-
view and discuss each advantage separately.
3.1. Tumor Localization. Prognostic information based on
biopsy other than diagnosis and grading are to quantify tu-
mor amount within the biopsy and to identify the location of
“index lesion” [22].
Given that Pca involves the gland in 3 distinctive ways,
with diﬀerent clinical implications. Speciﬁcally, (1) Pca can
involvethePZthroughmultipleorsinglePcafocioriginating
in diﬀerent prostate zones; (2) Pca can involve the TZ only
through multiple or single Pca foci; (3) through peripheral
zone Pca, which extends into the TZ.
Specimen orientation by marking the peripheral (prox-
imal) end could help in distinguishing these subgroups re-
spectively (Figure 3): in the ﬁrst subgroup, Pca harbours in
the marked proximal end, therefore Pca involves the poste-
rior subcapsular peripheral zone; in the second subgroup,
Pca lies only in the noninked end of one or more specimens
(distal), that could be interpreted as anterior zone or TZ can-
cer;ﬁnallythethirdsubgroup,Pcaliesinthewholespecimen
or both the ends of one or more specimens, that could be
interpreted as PZPca, which extends into the TZ.
Using the marking technique, we can add a new patho-
logical parameter: the cancer location within the biopsy
specimen.
3.1.1. Anterior (TZ) versus Posterior (PZ) Cancer. Based on
biopsy pathologist’s report, the distinction between transi-
tion or peripheral cancer is not easy, unless the whole spec-
imen is involved by cancer or the only positive biopsy is the
TZ while all negative cores were taken from the PZ.
Inking the peripheral end of biopsy, the posterior or an-
terior cancer location should be easy and reliable. In particu-
larwhenPcatouchesthenoninkedend(distal),thatcouldbe
interpreted as anterior cancer located in the subcapsular area
(Figure 4)[ 23]. This pathological feature could have poten-
tial clinical advantage in the surgical management. Pon-
holzer et al. showed that men, with at least one core with
cancer at the inked peripheral margin, had a 3.1-fold (95%
CI: 1.1–9.9) increased risk for locally advanced tumour stage
in the ﬁnal surgical specimen [7].
Peripheral cancer has a poor prognostic outcome com-
pared with transizion zone cancer [24], as Erbersdobler
et al. [25] showed in cases matched for cancer volume.
Although the distinction between subcapsular or anterior
gland lesions on surgical whole specimen has been showen
to have prognostic relevance, it remains unreliable on the
biopsy specimen due to lacking of the specimen orientation.
Therefore marking technique improves distinction between
anterior and posterior Pca.
TR TP
Ink
Ink
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Figure 3: Simulation of biopsy histology corresponding to 4
diﬀerent cancer foci (black circle) and normal tissue (light blue =
PZ, white = TZ) in the prostate gland (longitudinal view) using
2 needle biopsy tracks: transrectal (TR; arrows) and transperineal
(TP; dotted arrows). Ink = inked peripheral core end.
AFS
PZ PZ
U
Figure 4:Transversesectionofthewholeprostateonhistologyafter
nerve-sparing surgery. The black circle shows the anterior cancer
location. Anterior ﬁbromuscular stroma (AFS), urethra (U). Biopsy
track (arrow) in the anterior zone.
3.1.2. Subcapsular versus Non-Subcapsular Cancer. The pa-
thology report may describe the distance or contact with the
inked margins in cases of intraprostatic cancer (Figure 5).
Pca is not in contact with the marked end, which means nor-
mal tissue is present in the subcapsular area, and the distance
c o u l db em e a s u r e di ne a c hs p e c i m e n .4 Prostate Cancer
pT2a
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Figure 5: Transverse section of the whole prostate on histology
showing peripheral cancer (black circle) and biopsy track (arrow).
The cancer (CA) does not reach the capsule or the inked peripheral
end (arrowhead) of biopsy specimen.
The mean core biopsy length is 14.5mm measured
on histology slide using a needle sample notch of 18mm
(MaxiCore Bard) in our experience [11, 12] and 14.1mm in
transperineal approach using standard Tru-Cut needle [26].
The distance from cancer to the inked peripheral end (peri-
capsular tissue) can be measured on slides. The distance de-
pends on the degrees of the of incidence angle of the needle
on the prostate. This angle is composed by the needle pene-
tration axis and posterior capsule axis, which ranges 15◦–89◦
(mean 30◦) adopting transrectal approach.
3.1.3. Extraprostatic Cancer. Initially, the positive predictive
value of an individual positive core for the location of extra-
capsular extension was considered not suﬃcient to guide the
surgical decision to spare or excise a neurovascular bundle
[27]. Therefore, the clinical information provided by indi-
vidually labelled (cancer site itself) was previously stated not
useful and not convenient to justify the increased associated
costs [18]. Surprisingly, when Ponholzer et al. [7] considered
the cancer location within the core (cancer located at the
peripheral end of the specimen), they showed a signiﬁcant
correlation to pT3/pT4 stage (P = 0.04) in multivariate
analyses of 100 cases.
The marking technique could be useful to biopsy ori-
entation distinguishing which end of the PB contains non-
prostate tissue: nerve ﬁbres, seminal vesicle, striated muscle
or adipose tissue, Cowper gland, and ﬁbrous capsule. All
these tissue may be involved by Pca. Intraprostatic nerves
(large or small ﬁbres) are located in all subcapsular areas,
therefore orientation by marking one biopsy end helps in
distinction from anterior versus posterior perineural inva-
sion. Soft tissues are rarely sampled by biopsy; however, if
the tumor invasion of soft tissue has been described in the
pathology report, this deﬁnes extraprostatic invasion (T3).
The posterior or anterior location of extraprostatic extension
based on clinical parameters and specimen marking should
be easy and reliable.
The distinction of posterior or anterior invasion has
importance also for radiation therapist in order to improve
localcancercontrol,giventhatimagingtechniquesaresome-
times unreliable to detect early T3.
3.1.4. Application to Transperineal Biopsy. Using the tran-
sperineal approach, the needle biopsy track follows a lon-
gitudinal axis. The marking technique helps to distinguish
proximal/apical (outer or perineal location) from distal/base
(inner or cranial location). The advantages that we report for
transrectal approach can be considered the same for tran-
sperineal.
3.2.AtypicalLesions(orASAP)Localization,PlanningRebiop-
sy Strategy, and PIN. Hypothetically, one could have four
clinical scenarios if marking the peripheral end of the biopsy
has been reported after ASAP diagnosis.
(1) ASAP touches the marked proximal end. Therefore
atypic glands are located in the subcapsular periph-
eral zone, thus missed cancer could be located more
proximally to the point at which the biopsy needle
was ﬁred. Clinical implication in repeated biopsy is
that the needle should be activated just before inser-
tion into the prostate capsule in order to sample all of
the subcapsular area.
(2) ASAP is not in contact with the marked proximal end
or the distal end. That could be interpreted as tan-
gential sampling of underlying cancer located later-
ally to the initial biopsy track: in particular when 2
ASAP foci are observed in the same specimen, the
tangential sampling of lateral cancer should be sus-
pected. Since ASAP has been interpreted [28–30]a s
tangential sampling of the underling cancer, addi-
tional biopsy should be taken also laterally to original
ASAP track. Additional biopsy should be taken at the
margins of the ASAP location according the trans-
verse axis, far lateral and medial to former biopsy
track, and according the longitudinal axis, proximal
or distal to former biopsy track.
(3) ASAP lies in the noninked end of the specimen
(distal),whichcouldbeinterpretedasfailedsampling
ofanteriorcancer.Thereforeatypicglandsarelocated
in the far anterior zone, thus missed cancer could
be located more anteriorly to the point at which the
biopsy needle is sampled. Clinical implication in
repeated biopsy is that the needle should be inserted
1-2cm deeper in order to sample all the anterior area
including the subcapsular area according to gland
anatomy.
These advantages must be considered as potential, since
no case series have never tested the usefulness of the marking
technique. Cancer detection rates on repeat biopsy for ASAP
using an extended core biopsy scheme, the cancer detection
rate remained as high as 36% to 59.1% [28]o nﬁ r s tr e p e a t
biopsy and 16% on second repeat biopsy [29]. Because most
cancers were found in the same region as the ASAP on repeat
biopsy, and because 20% to 45% of cancers can be found
outside the area of ASAP, a systematic Rebiopsy of the pros-
tate is recommended by Canadian guidelines with additional
targeted cores [30, 31].Prostate Cancer 5
Diﬀerent PB techniques were used to minimize false-
negativebiopsiesinrepeatbiopsypopulations, inourexperi-
enceanddailypracticeweusethisinformationinadditionto
other clinical and pathologic features. Saturation biopsy may
be considered in high-risk cases (e.g., rising PSA, abnormal
DRE, persistent ASAP) with at least 2 previous negative
extended biopsies [15]. The incidence of prostate cancer at
the second and third biopsy using saturation biopsy scheme
versus 18-core set was 22.6% versus 10.9% (P = 0.02) and
6.2% versus 0% (P = 0.01), respectively [32, 33].
As we described above for Pca and ASAP, we may detect
high-grade PIN location, transition, or peripheral zone PIN
based on marking technique. Clinical relevance of this infor-
mation remains to be addressed by research studies.
3.3. Planning Surgical Strategy. I nt h ee r ao fe x t e n d e db i o p s y
schemes (10–18 cores), which are now the standard of care
for detection of prostate cancer, the location of extracapsular
extension on prostatectomy specimen correlated well with
a positive biopsy site in 70% patients [10]. Preoperative
reliablecancermapbasedonextendedbiopsycouldbeuseful
to reduce positive surgical margins. In fact, aims of surgery
are improving control and reduce postoperative erectile
dysfunctionusingintrafascial(pericapsular)glanddissection
leavingoffewmmofextraprostatictissueoranytissueonthe
surgical specimen.
Previously, Rogatsch et al. [34] evaluated the rectal mar-
gin (inked) of each core biopsy and the distance from cancer
to the inked rectal end, in a selected screening population
using 10-core biopsy. They showed that the predictive value
of an individual positive apical biopsy was only 28.8% for
predicting surgical margin positivity. They concluded that
thevalueofpreoperativeindividuallylabeledcoresandrectal
end inking were limited. Results were incomplete because
they did not analyse individually all labeled specimens. In
fact, PB of the mid, anterior, and base of the prostate were
placed together in a tissue cassette whereas specimens from
the apex and transition zone were placed in separate cas-
settes.
Initially,Walsh[35]notedthatsurgicalpositivemarginat
theapexoccursduringreleaseofthedorsalveincomplexand
striated sphincter and not during nerve-sparing procedure.
Recently, Nielsen et al. [36] modiﬁed initial poit of view
introducing a link between apical dissection and nerve-
sparing. In fact the high anterior release of the levator fascia
in open radical retropubic prostatectomy provided excellent
oncological results (1.3% positive margin) and was asso-
ciated with improved postoperative sexual function (93%
versus 77%). The proper selection criteria was based on
Tsutzuki nomogram and cancer extent on apical biopsies
[37].Theprobabilityofside-speciﬁcextraprostaticextension
was based on prostate needle biopsy pathology. They were
able to predict with 90% accuracy which men would be ideal
candidates for nerve-sparing surgery.
We suggest that the multiple measures of carcinoma ex-
tent (volume) in the biopsy, tumor grade associated with in-
dividually labeled biopsy, as well as cancer at the inked
peripheral end (or distance) may be the best means of
predicting the risk of extracapsular disease and/or a positive
surgical margin.
Furthermore, tumor spread in prostate needle biopsy has
become critical in the subsequent management of salvage
treatment (surgery or cryoablation) for recurrent prostate
carcinoma after radiotherapy. Mapping distribution of can-
cer based on biopsy is important to assess tumor spread, and
itisessentialforplanning thesalvagecryosurgery.Themark-
ing technique has a value to determine the level of depth of
tumour (peripheral or periurethral, posterior or anterior)
and planning of salvage cryoablation [38].
3.4. Selection Criteria for Focal Therapy (FT) and Active
Surveillance (AS). The anatomical cancer localization has
gained more clinical and prognostic relevance in focal treat-
mentplanning.Identiﬁcationofindexlesion:grade,anatom-
ical extension (size, shape, side, and zone) has gained im-
portance in focal treatment strategy. We believe that Pca ori-
entation within each biopsy specimen could add useful in-
formation in this clinical setting.
In the selection of patients for FT, the transperineal sat-
uration biopsy using the brachitherapy grid has been consid-
ered the best method to have three-dimension pathological
mapping and to select patient to focal therapy [39]. Despite
the requirement for general anaesthesia and a potential
increased urinary retention rate, novel transperineal map-
ping schemes, when employing a brachytherapy grid tem-
plate, allow for more accurate sampling of the entire gland.
The remit of prostate biopsy now lies beyond pure diagnos-
tics and has become an essential tool for determining the
optimal therapeutic approach [39, 40]. The biopsy orienta-
tion and exact location of cancer within the specimen could
be useful to depict anatomical location of Pca foci and to
guide FT.
In the selection of patient for AS, the cancer location
within the biopsy has not yet been considered a selection
criterion. However, a diﬀerent cancer location within the
gland could not have the same natural history or the same
success rate of therapeutic options: an example is given
by subcapsular cancer or located at the edge of the gland:
(1) early extraprostatic invasion has been observed in small
volumePcaarisinginthesubcapsulartissue[41],(2)positive
surgical margins have been reported in 1.5–38%Pca located
at the edge of the apical/anterior even if intraprostatic (pT2).
Therefore AS in small cancer located at the edge of the gland
could have a negative impact on radical treatment.
4. Cost Reduction
The cost of histopathologic evaluation is based on number of
individually labeled specimen containers. Submitting biopsy
coresindividuallyraisesthecostofpathologicevaluationsig-
nificantly while important prognostic information is lost
when the samples are bundled into fewer containers. Mark-
ing technique is an easy method to reduce cut costs and
specimen identiﬁcations. By reducing the number of spec-
imen containers from 12 to 6, including 2 cores in each
cassette, the potential savings may be in hundreds of million
per year.6 Prostate Cancer
Firoozi et al. showed for the ﬁrst time that marking
tissue-labeling is a cost-eﬀective manner in 452 cases, while
maintaining ability to glean important prognostic informa-
tion from each core [10].
Thistissue-labelingtechniquewassuccessfullyappliedby
Scattoni et al. in 617 patients [14]. The 24 cores were put on
sponge tissue in 7 diﬀerent sandwich cassettes and individ-
ually inked (Figure 1)w i t hd i ﬀerent colors to mark the site
from which they were collected. Each single core was indi-
vidually marked (black, blue, green, and orange ink). They
were able recognized to each specimen separately according
to anatomical sampling (lateral, subcapsular, sextant, and
transition zone cores) besides 3 or 4 biopsy specimens were
collected in the same cassette.
Tissue-labeling protocol did not increase the procedure
time or introduce any tissue artifacts.
5. Discussion
Our review supports marking the distal end of PB, since it
allowsspatialspecimenorientation.Specimenorientationby
ink marking is simple, reproducible, and does not require
sophisticated technical aids. It takes approximately 2min for
the nurse to ink the cores at the peripheral end. It takes only
few minutes for the incorporation into the ﬁnal pathology
report. It can be obtained without any patient discomfort or
risk. Any tissue artefact was observed.
Furthermore the technique allows single specimen iden-
tiﬁcation even if 2 or more cores are embedded in the same
cassettes using diﬀerent colours. Thus marking technique
reduces costs while maintaining ability to glean important
prognostic information from each core.
We showed the clinical implications in repeated strategy
biopsy based on relationship between inked end and atypical
lesion: site, depth of needle sampling, and lateral sampling
adjusted in each case according tangential sampling of main
cancer foci.
Wereviewedthatmarkingtechniquehasseveralpotential
advantages for urologist and pathologist, but the scientiﬁc
evidenceinfavourhasbeensupportedbyexpertopinionand
smallnumberofclinicalstudiesderivedfrompublishedliter-
ature. The pathological and anatomical correlation between
biopsy and surgical specimen could be considered as good
evidence to support this ancillary procedure. However, we
deﬁned clinical advantages as “potential” because further
studies are needed to conﬁrm all those advantages. These
substantial beneﬁts outweigh the additional eﬀort by the
pathologist.
6. Conclusions
Using the marking technique, we can add a new pathological
parameter: pathological orientation or biopsy polarity. Can-
cer or atypical lesions can be accurately located within the
biopsy specimen and integrated to biopsy approach. It drives
several potential advantages in cancer diagnosis or isolated
atypical lesions, in particular spatial localization within the
biopsy (transition versus peripheral zone, anterior versus
posterior, and subcapsular versus intraparenchima) should
be easy and reliable.
Peripheral end marking is low cost, easy, and repro-
ducible. It may also reduce costs allowing each specimen
identiﬁcation and analysis.
Abbreviations and Acronyms
AS: Active surveillance
ASAP: Atypical small acinar proliferation
FT: Focal therapy
PB: Prostate biopsy
Pca: Prostate cancer
PIN: Prostatic intraepithelial neoplasia
PZ: Peripheral zone
TRUS: Transrectal ultrasound
TZ: Transizion zone.
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